Market By Dosages, Formulation And Geography | Forecast 2019-2027
The hyperphosphatemia drugs market in Latin America has been projected to grow in terms of revenue and proliferate with a CAGR of 17.20% during the forecasting years 2019-2027, according to a report by Triton Market Research.
The countries considered in the report on Latin America’s hyperphosphatemia drugs market are:
• Rest of Latin America
Latin America can be considered as a primary growth market for hyperphosphatemia drugs, which is driven by a number of global companies involved in the manufacture and distribution of complex hyperphosphatemia drugs. Several key factors are driving sustainable long-term growth across the segment in the region. This includes the higher old-age mortality rate driven by hyperphosphatemia cases, better access to healthcare facilities, rising cases of obstetric problems and superior accessibility of advanced healthcare services.
Report scope can be customized per your requirements. Request For Customization
The hyperphosphatemia drugs market is driven by the increasing public awareness about the disease. The National Center for Chronic Disease Prevention and Health Promotion established the Chronic Kidney Disease Initiative to raise awareness of hyperphosphatemia & kidney diseases and their early detection and improve the quality of life of individuals with these diseases. Similarly, the National Kidney Foundation has formulated a strategic plan to spread awareness about the prevention and treatment of kidney diseases. Initiatives were taken up by vendors to promote their drug candidates also help to create awareness of hyperphosphatemia and increase the use of drugs for the treatment.
In the current scenario, the hyperphosphatemia drugs market is growing due to rising osteoporosis cases and changing dietary habits. However, there are some government policies and procedures which are hindering the market growth. Strict government regulation for the use of these drugs and the presence of alternatives such as hemodialysis and Sevelamer hydrochloride are the major factors which are hindering the growth of the hyperphosphatemia drugs market. Triton’s report on the hyperphosphatemia drugs market studies in detail the key insights, key market trends, Porter’s five force model, key buying outlook and guidelines related to phosphate binders.
Market By Type, Application, E ..VIEW REPORT
Market By Offerings, Technolog ..VIEW REPORT
Market By Device Type, Therape ..VIEW REPORT
Market By Type, Application, T ..VIEW REPORT
Market By Technology, Applicat ..VIEW REPORT
Market By Application, Type, E ..VIEW REPORT
Market by Therapeutics, Diagno ..VIEW REPORT
1. LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. PORTER’S FIVE FORCE MODEL
2.2.1. THREAT OF NEW ENTRANTS
2.2.2. BARGAINING POWER OF BUYERS
2.2.3. BARGAINING POWER OF SUPPLIERS
2.2.4. THREAT OF SUBSTITUTE PRODUCT
2.2.5. INTENSITY OF COMPETITIVE RIVALRY
2.3. VENDOR SCORECARD
2.4. KEY BUYING OUTLOOK
2.5. KEY INSIGHTS
2.6. KEY MARKET TRENDS
2.7. GUIDELINES RELATED TO THE PHOSPHATE BINDERS
2.8. MARKET DRIVERS
2.8.1. CHRONIC DISORDERS ARE INCREASING RAPIDLY
2.8.2. INCREASE IN PUBLIC COGNIZANCE
2.8.3. INCREASE IN GERIATRIC POPULATION
2.9. MARKET RESTRAINTS
2.9.1. SIDE-EFFECTS RELATED TO THE USAGE OF HYPERPHOSPHATEMIA DRUGS
2.9.2. STRICT FOOD AND DRUG ADMINISTRATION (FDA) REGULATIONS
2.10. MARKET OPPORTUNITIES
2.10.1. RISE IN THE AGING POPULATION
2.11. MARKET CHALLENGES
2.11.1. ALTERNATIVE DIALYSIS TECHNIQUES
2.11.2. ACCESSIBILITY OF DRUGS IS LIMITED
2.11.3. NON-ADHERENCE TO TREATMENT REGIMES
3. HYPERPHOSPHATEMIA DRUGS MARKET OUTLOOK - BY DOSAGES
4. HYPERPHOSPHATEMIA DRUGS MARKET OUTLOOK - BY FORMULATION
4.1.1. CALCIUM-BASED PHOSPHATE BINDERS
4.1.2. ALUMINUM-BASED PHOSPHATE BINDERS
4.1.3. MAGNESIUM-BASED PHOSPHATE BINDERS
4.1.4. IRON-BASED PHOSPHATE BINDERS
4.1.5. OTHER PHOSPHATE BINDERS
5. HYPERPHOSPHATEMIA DRUGS MARKET - REGIONAL OUTLOOK
5.1. LATIN AMERICA
5.1.1. COUNTRY ANALYSIS
126.96.36.199. REST OF LATIN AMERICA
6. COMPETITIVE LANDSCAPE
6.1. JOHNSON AND JOHNSON
6.2. ZERIA PHARMACEUTICAL
6.3. AMAG PHARMACEUTICALS
6.5. BRUNO FARMACEUTICI S.P.A.
6.6. ROCHE DIAGNOSTICS CORPORATION
6.7. ROYAL DSM N.V.
6.10. ULTRAGENYX PHARMACEUTICAL, INC.
6.11. FERMENTA BIOTECH, LTD.
6.12. BIOTECH PHARMACAL
6.13. SUN PHARMACEUTICAL INDUSTRIES, LTD.
6.14. KERYX BIOPHARMACEUTICALS, INC.
6.15. FRESENIUS MEDICAL CARE
6.16. PFIZER, INC.
7. METHODOLOGY & SCOPE
7.1. RESEARCH SCOPE
7.2. SOURCES OF DATA
7.3. RESEARCH METHODOLOGY
TABLE 1 LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)
TABLE 2 PHOSPHOROUS LEVELS IN SELECT FOODS
TABLE 3 LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 ($ MILLION)
TABLE 4 DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE
TABLE 5 LATIN
AMERICA HYPERPHOSPHATEMIA DRUGS MARKET COUNTRY ANALYSIS 2019-2027 ($ MILLION)
FIGURE 1 PORTER’S FIVE FORCES MODEL OF HYPERPHOSPHATEMIA DRUGS MARKET
FIGURE 2 IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017
FIGURE 3 RATE OF ADHERENCE TO PHOSPHATE BINDERS
FIGURE 4 LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET IN CALCIUM-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)
FIGURE 5 LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET IN ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)
FIGURE 6 LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET IN MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)
FIGURE 7 LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET IN IRON-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)
FIGURE 8 LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET IN OTHER PHOSPHATE BINDERS 2019-2027 ($ MILLION)
FIGURE 9 LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET SHARE 2018 & 2027 (%)
FIGURE 10 LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 11 BRAZIL HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 12 MEXICO HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 13 REST OF LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)